Headlines about AstraZeneca (NYSE:AZN) have been trending somewhat positive on Tuesday, Accern reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. AstraZeneca earned a coverage optimism score of 0.25 on Accern’s scale. Accern also assigned news articles about the company an impact score of 44.8979539026924 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Global Pulmonary Drugs Market 2018- AstraZeneca plc, Bayer AG, Teva Pharmaceutical Industries Ltd (theanalystfinancial.com)
- Stocks Performances and Technical’s to scrutinize – AstraZeneca PLC, NYSE: AZN), Geron Corporation, (NASDAQ … (dailynysenews.com)
- BRIEF-Highmark Inc Signs Outcomes-Based Agreement With Astrazeneca For Symbicort (reuters.com)
- Highmark Inc. Signs Outcomes-Based Agreement with AstraZeneca for Symbicort (prnewswire.com)
- An Intrinsic Calculation For AstraZeneca PLC (LON:AZN) Shows It’s 34% Undervalued (finance.yahoo.com)
A number of equities research analysts recently issued reports on the company. JPMorgan Chase raised AstraZeneca from a “neutral” rating to an “overweight” rating in a research note on Friday, December 29th. Zacks Investment Research lowered AstraZeneca from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. BMO Capital Markets set a $38.00 price target on AstraZeneca and gave the stock a “buy” rating in a research note on Wednesday, January 10th. Leerink Swann reissued a “market perform” rating and set a $36.00 price target (up previously from $33.00) on shares of AstraZeneca in a research note on Thursday, January 18th. Finally, ValuEngine raised AstraZeneca from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 3rd. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $38.12.
NYSE AZN traded up $0.05 during trading hours on Tuesday, hitting $35.80. The company had a trading volume of 2,122,946 shares, compared to its average volume of 4,087,993. AstraZeneca has a fifty-two week low of $28.43 and a fifty-two week high of $36.75. The company has a market cap of $91,994.78, a P/E ratio of 8.37, a P/E/G ratio of 1.86 and a beta of 0.62. The company has a current ratio of 0.80, a quick ratio of 0.62 and a debt-to-equity ratio of 0.93.
AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Friday, February 2nd. The company reported $1.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.86. The firm had revenue of $5.78 billion during the quarter, compared to the consensus estimate of $5.49 billion. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. The firm’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.21 EPS. sell-side analysts forecast that AstraZeneca will post 1.69 EPS for the current fiscal year.
The firm also recently announced a semiannual dividend, which was paid on Monday, March 19th. Stockholders of record on Friday, February 16th were paid a dividend of $0.95 per share. The ex-dividend date of this dividend was Thursday, February 15th. This represents a dividend yield of 5.62%. AstraZeneca’s dividend payout ratio is presently 32.01%.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.